Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application source : Www.biospace.com save search
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | News | $17.65 -2.4% 4K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SZLSF | $0.039 -11.46% 950
|
n/a
| Email alert
Add to watchlist
management life update sciences for order application
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published: 2024-04-04 (Crawled : 23:00) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -2.33%
H: 1.64%
C: -4.91%
ecur-506 fda drug treatment clearance for application trial
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Published: 2024-04-03 (Crawled : 14:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -0.14%
H: 4.43%
C: -5.11%
precision health meeting application
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 2.45%
H: 0.87%
C: -0.43%
fda namodenoson application trial
Infinant Health Announces Submission of Orphan Drug Designation Application
Published: 2024-04-02 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.77%
H: 0.8%
C: 0.74%
drug health designation application submission
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Published: 2024-04-02 (Crawled : 11:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K
|
Health Technology
|
| O: -1.76%
H: 0.0%
C: -1.91%
anemia authorization treatment pharmaceuticals application
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: 8.7%
H: 3.33%
C: -8.67%
ctim-76 application therapeutics
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.88%
C: 0.02%
vx-407 fda drug disease kidney treatment clearance application
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Published: 2024-03-01 (Crawled : 15:00) - biospace.com/
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
MNKTQ | $0.12 -66.67% 39K
|
Manufacturing
| Email alert
Add to watchlist
acthar fda drug approval gel application
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 10.45%
H: 11.61%
C: -7.38%
ata3219 fda lupus clearance application therapy
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
tevimbra fda license application
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA®
Published: 2024-02-19 (Crawled : 17:00) - biospace.com/
OCUL | News | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
| Email alert
Add to watchlist
dextenza drug health sciences application therapeutics
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
lung license cancer cell application advanced
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Published: 2024-02-14 (Crawled : 15:30) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 6.48%
H: 0.0%
C: -6.07%
ata3219 drug lupus treatment application submission
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.